6 Key Ways Real-World Data Is Accelerating Breast Cancer Therapies

Breast cancer remains a significant global health challenge, with its complexity and heterogeneity demanding tailored therapeutic approaches. Recent advancements, such as HER2 and CDK4/6 inhibitors, have improved patient outcomes, yet challenges like treatment resistance and metastatic disease management persist. Real-world data (RWD) is increasingly vital for advancing breast cancer research and therapy development.

Quest Diagnostics offers a comprehensive array of deidentified therapeutic area datasets, including the Test-Based Cohort and Patient-Centric Cohort, encompassing over 1.7 million patient records and more than 25 key biomarkers. These datasets facilitate clinical trial feasibility studies, patient journey mapping, real-world evidence generation, biomarker discovery, treatment pathway optimization, and market access discussions. Quest's datasets provide near real-time lab data access, enabling immediate evidence generation and enhancing clinical decision-making. By leveraging these datasets, researchers and clinicians can address pressing challenges in breast cancer research, leading to more effective and personalized treatment strategies, driving innovation, and ultimately improving patient outcomes.